We have compiled a variety of clinical studies that you can receive upon request. These studies provide key evidence regarding the efficacy of therapies, pumps, CGM and more.
Use the filters to quickly find the information you need.
Impact of insulin pump therapy on key parameters of diabetes management and diabetes related emotional distress in the first 12 months
Oldham V et al. Diabetes Res Clin Pract. 2020 Aug; 166:108281.
Pump Therapy vs. Multiple Daily Injections
Observational prospective study to assess the glycaemic benefits and patient satisfaction of Type 1 adults (n=47) within the first 12 months after commencing CSII therapy.
- CSII therapy offers greater flexibility of insulin delivery and therefore patients make better emotional adjustments
- Patients integrate CSII therapy into their daily lives with greater ease and motivation and they experience less emotional distress and burned out feeling
- Diabetes related emotional distress is reduced with CSII as patients experience better glucose control, reduced fear of hypoglycaemia, better self-esteem, decreased stress, greater ease of travel and more active participation in social and recreational activities.
MiniMed® 670G Real World Data
PARAMETERS ASSESSED:
Mean sensor glucose (SG) level
Time spent in the target range (TIR) – 3.9-10mmol/L
Time spent in hypoglycaemia - < 3.9mmol/L
Time spent in hyperglycaemia - > 10mmol/L
SmartGuard® Auto Mode Technology - Hybrid Closed Loop System
Retrospective Analysis of Carelink™ database (patient self-uploaded electronic data base) 3,141 subjects with Diabetes Mellitus who completed 3 months of SmartGuard® Auto Mode.
Comparison were made between Manual Mode and SmartGuardTM Auto Mode data
From Manual Mode usage to SmartGuard® Auto Mode usage:
The time spent in the target range(TIR) increased from 66.0% to 73.3%.
The time spent in hypoglycaemia <3.9 mmol/L decreased from 2.7% to 2.1%.
The time spent in hyperglycaemia >10.0 mmol/L decreased from 31.4% to 24.6%
Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.
Garg et al. DIABETES TECHNOLOGY & THERAPEUTICS. Volume 19, Number 3 2017
Hybrid Closed Loop Insulin Delivery System (SmartGuard Auto Mode)
A Prospective before and after Multi-centre study assessing SmartGuard® Auto Mode vs Manual Mode (SAP) in adolescents(n= 30)and adults(n=94) with Type 1 Diabetes over 3 months.
The Pivotal study has showed that MiniMed® ™ 670G can be used by adolescents and adults with Type 1 diabetes in an outpatient setting with no episodes of severe hypoglycaemia and DKA in over 12,000 patient days of use.
The SmartGuard® Auto Mode feature was associated with significant HbA1c reduction, from baseline, 7.8% to 7.2% in adolescents and 7.4% to 6.9% in adults.
Additionally the SmartGuard® Auto Mode feature was associated with an increased time spent in glycaemic target range (3.9-10.0mmol/L), reducing both hypoglycaemia and hyperglycaemia, in both adolescents and adults.
Reduction in Hypoglycemia With the Predictive Low-Glucose Management System: A Long-term Randomized Controlled Trial in Adolescents With Type 1 Diabetes.
Abraham, M , et al. DIABETES CARE. 2018, Feb; 41 (2): 303-310
Insulin Pump Therapy with automated predictive insulin suspension
Multi-centre, unblinded randomised controlled phase 3 home trial over six months. 154 participants with type 1 diabetes aged 8-20 years on MiniMed® 640G were randomised to have the automatic suspend before low function on or off for the duration of six months.
- Children and adolescents spent approximately half the time in hypoglycaemia with fewer hypoglycaemic events with Suspend Before Low ON as compared with Suspend Before Low OFF.
- The lower hypoglycaemia exposure was consistent in subgroups of participants irrespective of age, duration of diabetes, HbA1c and hypoglycaemia awareness status.
- The reduction in hypoglycaemia was not associated with a deterioration of glucose control as measured by hyperglycaemia or HbA1c, nor in a reduction in quality of life.
“Let the Algorithm Do the Work” -Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients
Biester, T , A et al. DIABETES TECHNOLOGY & THERAPEUTICS. Vol 19. Number 3, 2017
Insulin Pump Therapy with automated predictive insulin suspension
Prospective, multicentre user evaluation assessing 6 weeks of SAP with Suspend Before Low vs 2 weeks of Sensor Augmented Pump Therapy Alone (no Suspend) in 24 paediatric patients.
Suspend Before Low:
- Reduced the number of instances in which the glucose level was < 3.9mmol without a significant change in mean glucose concentration or HbA1c.
- The study also looked at how patient behaviour (manual overrides and carbohydrate intake) affected glucose profiles following suspensions
- The study sets out some recommendations for educating patients on how to respond to the Suspend Before Low events
